PRLD (Prelude Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 07, 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Prelude Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

PRLD vs DMAC, RCKT, CYDY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Prelude Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price